Edinburgh Research Explorer

Short-Term Hemodynamic Effects of Apelin in Patients With Pulmonary Arterial Hypertension

Research output: Contribution to journalArticle

  • Lauren Brash
  • Gareth D. Barnes
  • Melanie J. Brewis
  • A. Colin Church
  • Simon J. Gibbs
  • Luke S.G.E. Howard
  • Geeshath Jayasekera
  • Martin K. Johnson
  • Neil McGlinchey
  • Joelle Onorato
  • Joanne Simpson
  • Colin Stirrat
  • Stephen Thomson
  • Geoffrey Watson
  • Martin R. Wilkins
  • Carrie Xu
  • David J. Welsh
  • David E. Newby
  • Andrew J. Peacock

Related Edinburgh Organisations

Open Access permissions



Original languageEnglish
Pages (from-to)176-186
Number of pages11
JournalJACC: Basic to Translational Science
Issue number2
Early online date28 Mar 2018
Publication statusE-pub ahead of print - 28 Mar 2018


Apelin agonism causes systemic vasodilatation and increased cardiac contractility in humans, and improves pulmonary arterial hypertension (PAH) in animal models. Here, the authors examined the short-term pulmonary hemodynamic effects of systemic apelin infusion in patients with PAH. In a double-blind randomized crossover study, 19 patients with PAH received intravenous (Pyr1)apelin-13 and matched saline placebo during invasive right heart catheterization. (Pyr1)apelin-13 infusion caused a reduction in pulmonary vascular resistance and increased cardiac output. This effect was accentuated in the subgroup of patients receiving concomitant phosphodiesterase type 5 inhibition. Apelin agonism is a novel potential therapeutic target for PAH. (Effects of Apelin on the Lung Circulation in Pulmonary Hypertension; NCT01457170)

    Research areas

  • apelin, APJ, human, pulmonary arterial hypertension

Download statistics

No data available

ID: 58994853